Synonym
Imirestat; AL-1576; AL-01576; Hoe-843; AL1576; AL01576; Hoe843.
IUPAC/Chemical Name
2,7-Difluorospiro(fluorene-9,4'-imidazolidine)-2',5'-dione
InChi Key
QCCHBHSAIQIQGO-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H8F2N2O2/c16-7-1-3-9-10-4-2-8(17)6-12(10)15(11(9)5-7)13(20)18-14(21)19-15/h1-6H,(H2,18,19,20,21)
SMILES Code
O=C1NC2(C(N1)=O)C3=C(C4=C2C=C(F)C=C4)C=CC(F)=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
286.24
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Gilbert PJ, Hartley TE, Troke JA, Turcan RG, Vose CW, Watson KV. Application of 19F-n.m.r. spectroscopy to the identification of dog urinary metabolites of imirestat, a spirohydantoin aldose reductase inhibitor. Xenobiotica. 1992 Jul;22(7):775-87. PubMed PMID: 1455900.
2: Chien JY, Banfield CR, Brazzell RK, Mayer PR, Slattery JT. Saturable tissue binding and imirestat pharmacokinetics in rats. Pharm Res. 1992 Apr;9(4):469-73. PubMed PMID: 1495891.
3: Carrington AL, Ettlinger CB, Calcutt NA, Tomlinson DR. Aldose reductase inhibition with imirestat-effects on impulse conduction and insulin-stimulation of Na+/K(+)-adenosine triphosphatase activity in sciatic nerves of streptozotocin-diabetic rats. Diabetologia. 1991 Jun;34(6):397-401. PubMed PMID: 1653157.
4: McCue BA, Park YH, Brazzell RK, Boltralik JJ. Capillary gas chromatographic-electron-capture assay for the aldose reductase inhibitor imirestat in lens and plasma. J Chromatogr. 1991 Apr 19;565(1-2):255-64. PubMed PMID: 1908477.
5: Brazzell RK, Mayer PR, Dobbs R, McNamara PJ, Teng RL, Slattery JT. Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man. Pharm Res. 1991 Jan;8(1):112-8. PubMed PMID: 1901647.
6: Vaidyanathan G, Jay M, Bera RK, Mayer PR, Brazzell RK. Scintigraphic evaluation of the ocular disposition of 18F-imirestat in rabbits. Pharm Res. 1990 Nov;7(11):1198-200. PubMed PMID: 2127314.
7: Brazzell RK, Wooldridge CB, Hackett RB, McCue BA. Pharmacokinetics of the aldose reductase inhibitor imirestat following topical ocular administration. Pharm Res. 1990 Feb;7(2):192-8. PubMed PMID: 2106677.
8: Pinkerton TC, Miller TD, Janis LJ. Effect of protein binding on the high-performance liquid chromatography of phenytoin and imirestat in human serum by direct injection onto internal surface reversed-phase columns. Anal Chem. 1989 May 15;61(10):1171-4. PubMed PMID: 2751110.
